Results 241 to 250 of about 309,043 (332)

Correction: Transarterial embolization for acute lower gastrointestinal bleeding: a retrospective bicentric study. [PDF]

open access: yesRadiol Med
Tiralongo F   +14 more
europepmc   +1 more source

Gastrointestinal Bleeding

open access: yes, 2020
Pamela Choi   +2 more
openaire   +1 more source

Effect of vepdegestrant, a PROTAC oestrogen receptor degrader, on dabigatran and rosuvastatin pharmacokinetics in healthy participants

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims To evaluate the effects of vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) oestrogen receptor degrader, on the pharmacokinetics of dabigatran (a P‐glycoprotein [P‐gp] substrate) and rosuvastatin (a breast cancer resistance protein [BCRP] substrate).
Derek Z. Yang   +9 more
wiley   +1 more source

Availability, use, efficacy and safety of bevacizumab in European hereditary haemorrhagic telangiectasia centres

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Introduction Bevacizumab, a vascular endothelial growth factor inhibitor, is used off‐label for treatment of severe anaemia related to epistaxis, gastrointestinal bleeding and/or severe hepatic arteriovenous malformations (HAVM) and right‐sided cardiac failure in patients with hereditary haemorrhagic telangiectasia (HHT).
Pernille D. Haahr   +18 more
wiley   +1 more source

Fostamatinib and the risk of acute aortic dissection in immune thrombocytopenia

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Immune thrombocytopenia (ITP) is a rare autoimmune disorder characterized by platelet destruction. While most patients respond to first‐ or second‐line therapies, a small subset is multirefractory. Fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, is a therapeutic option in these cases.
Paul Dalmas   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy